NFKB1 and endometrial cancer: Notably, inhibition of ERK5, deletion of MEK5, or inhibition of NF-kB sensitized endometrial cancer cells to the toxic effects of standard endometrial cancer chemotherapy (paclitaxel/carboplatin).